Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.73 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.73 |
| ▸ | NPSR1 | Q6W5P4 | 5/20 | 0.73 |
| ▸ | MEN1 | O00255 | 5/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.73 |
| ▸ | PTGDR2 | Q9Y5Y4 | 6/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 4/20 | 0.53 |
| ▸ | HTT | P42858 | 3/20 | 0.53 |
| ▸ | UBE2N | P61088 | 2/20 | 0.53 |
| ▸ | MITF | O75030 | 1/20 | 0.53 |
| ▸ | GLA | P06280 | 2/20 | 0.50 |
| ▸ | VDR | P11473 | 1/20 | 0.46 |
| ▸ | RAD52 | P43351 | 2/20 | 0.46 |
| ▸ | STAT3 | P40763 | 1/20 | 0.46 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.46 |
| ▸ | APAF1 | O14727 | 1/20 | 0.46 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL40572 | 1.00 | SMN1; SMN2 (0.73) | SMN1; SMN2MAPK1NPSR1MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL9815917 | 0.99 | SMN1; SMN2 (0.71) | SMN1; SMN2MAPK1NPSR1MEN1KMT2A | |
| SCHEMBL8161368 | 0.93 | SMN1; SMN2 (0.64) | SMN1; SMN2MAPK1NPSR1MEN1KMT2A | |
| SCHEMBL7240787 | 0.90 | MAPK1 (0.75) | SMN1; SMN2MAPK1NPSR1MEN1KMT2A | |
| SCHEMBL11757931 | 0.88 | MAPK1 (0.73) | SMN1; SMN2MAPK1NPSR1MEN1KMT2A | |
| SCHEMBL1061587 | 0.87 | MAPK1 (0.71) | SMN1; SMN2MAPK1NPSR1MEN1KMT2A | |
| SCHEMBL4804002 | 0.87 | MAPK1 (0.71) | SMN1; SMN2MAPK1NPSR1MEN1KMT2A | |
| SCHEMBL76379 | 0.87 | MAPK1 (0.71) | SMN1; SMN2MAPK1NPSR1MEN1KMT2A | |
| SCHEMBL8087132 | 0.85 | NPSR1 (0.72) | SMN1; SMN2MAPK1NPSR1MEN1KMT2A | |
| SCHEMBL13081865 | 0.85 | SMN1; SMN2 (0.68) | SMN1; SMN2MAPK1NPSR1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 236 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4661890-A1 | PTP1B/TC-PTP DUAL INHIBITORS AND PROTEIN DEGRADERS | Purdue Research Foundation (US) | 2025-12-17 | — | — | EP | claimed |
| WO-2024167565-A1 | PTP1B/TC-PTP DUAL INHIBITORS AND PROTEIN DEGRADERS | PURDUE RESEARCH FOUNDATION (US) | 2024-08-15 | — | — | WO | claimed |
| US-12624018-B1 | Inhibitors of RIPK2 and medical uses thereof | ODYSSEY THERAPEUTICS, INC. (US) | 2026-05-12 | — | — | US | disclosed |
| EP-4727647-A1 | GLYCOGEN SYNTHASE KINASE 3 INHIBITORS AND USES THEREOF | The Broad Institute Inc. (US) | 2026-04-22 | — | — | EP | disclosed |
| EP-4727929-A2 | 5'-MODIFIED MONOMERS, OLIGONUCLEOTIDES AND DOUBLE-STRANDED RNAS | Alnylam Pharmaceuticals, Inc. (US) | 2026-04-22 | — | — | EP | disclosed |
| EP-4724417-A1 | TRICINE AND CITRIC ACID-BASED CATIONIC LIPIDS WITH AROMATIC HEAD GROUPS | Sanofi (FR) | 2026-04-15 | — | — | EP | disclosed |
| EP-4724418-A1 | TRICINE AND CITRIC ACID-BASED CATIONIC LIPIDS | Sanofi (FR) | 2026-04-15 | — | — | EP | disclosed |
| EP-4724456-A1 | STEROL-BASED CATIONIC LIPIDS WITH AROMATIC HEAD GROUPS | Sanofi (FR) | 2026-04-15 | — | — | EP | disclosed |
| EP-4709735-A1 | OLIGONUCLEOTIDE SYNTHESIS USING CYCLIC-PHOSPHOROUS NUCLEOSIDES | Eli Lilly and Company (US) | 2026-03-18 | — | — | EP | disclosed |
| WO-2026043875-A1 | SYNTHESIS OF OXEPANOPROLINES | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2026-02-26 | — | — | WO | disclosed |
| EP-4688758-A1 | VERDAZYL COMPOUNDS AS CONTRAST AGENTS FOR MAGNETIC RESONANCE IMAGING OF KIDNEYS | Yellowbird Diagnostics Inc. (CA) | 2026-02-11 | — | — | EP | disclosed |
| EP-4003319-A2 | HDAC6 INHIBITORS AND USES THEREOF | Eikonizo Therapeutics, Inc. (US) | 2022-06-01 | — | — | EP | disclosed |
| EP-4003335-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 AND USES THEREOF | Dana-Farber Cancer Institute, Inc. (US) | 2022-06-01 | — | — | EP | disclosed |
| WO-2022099210-A1 | CROSSLINKING COMONOMERS FOR HIGH PERFORMANCE DEGRADABLE THERMOSETS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2022-05-12 | — | — | WO | disclosed |
| EP-3993818-A2 | CD38-BINDING AGENTS AND USES THEREOF | Kleo Pharmaceuticals, Inc. (US) | 2022-05-11 | — | — | EP | disclosed |
| WO-2022092295-A1 | β-STRAND TYPE CROSSLINKED PEPTIDE | Ｘｅｎｏ－Ｉｎｔｅｒｆａｃｅ株式会社 | 2022-05-05 | — | — | WO | disclosed |
| WO-2022076922-A1 | N-ACETYLGALACTOSAMINE(GAlNAc)-DERIVED COMPOUNDS AND OLIGONUCLEOTIDES | ADARX PHARMACEUTICALS, INC. (US) | 2022-04-14 | — | — | WO | disclosed |
| EP-3980404-A1 | COMPOUNDS FOR THE TREATMENT OF KINASE-DEPENDENT DISORDERS | Exelixis, Inc. (US) | 2022-04-13 | — | — | EP | disclosed |
| WO-2022066678-A1 | TES-BASED CATIONIC LIPIDS | TRANSLATE BIO, INC. (US) | 2022-03-31 | — | — | WO | disclosed |
| EP-3947382-A1 | COMPOUNDS FOR USES IN PHARMACOLOGICAL INDUCTION OF HBF FOR TREATMENT OF SICKLE CELL DISEASE AND BETA-THALASSEMIA | Academia Sinica (TW) | 2022-02-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12624018-B1 | Inhibitors of RIPK2 and medical uses thereof | RIPK2, RIPK1, RIPK4 | SMN1; SMN2 1842/4885MAPK1 475/4885NPSR1 4783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.